The US Food and Drug Administration (FDA) requested the four Gadolinium‐Based Contrast Agents (GBCA) New Drug Application (NDA) holders to investigate the effects of gadolinium (Gd) retention on fetal and… Click to show full abstract
The US Food and Drug Administration (FDA) requested the four Gadolinium‐Based Contrast Agents (GBCA) New Drug Application (NDA) holders to investigate the effects of gadolinium (Gd) retention on fetal and neonatal development in mice and juvenile non‐human primates (NHP) as well as the effects of repeated GBCA administrations on behavioral, neurological, and histopathological endpoints.
Keywords:
juvenile non;
contrast agents;
non human;
human primates;
based contrast;
gadolinium based
Journal Title: Birth Defects Research
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Birth Defects Research
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!